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DOI 10.1016/j.ccr.2010.10.019SUMMARYmTORC1 is a validated therapeutic target for renal cell carcinoma (RCC). Here, analysis of Tsc1-
deficient (mTORC1 hyperactivation) mice uncovered a FoxO-dependent negative feedback circuit con-
straining mTORC1-mediated renal tumorigenesis. We document robust FoxO activation in Tsc1-deficient
benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal
tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in
most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive
RCCs and benign renal tumor subtypes. Mechanistically, integrated analyses revealed that FoxO-mediated
block operates via suppression of Myc through upregulation of the Myc antagonists, Mxi1-SRa
and mir-145, establishing a FoxO-Mxi1-SRa/mir-145 axis as a major progression block in renal tumor
development.INTRODUCTION
The mammalian target of rapamycin complex 1 (mTORC1)
serves as the key regulator of protein synthesis and cell growth
via phosphorylation of a variety of downstream targets, including
S6 Kinase and 4E-BP1 (Ma and Blenis, 2009; Wullschleger
et al., 2006), and plays a critical role in the regulation of cell
growth, angiogenesis, and metabolism in many human cancers,
including renal cell carcinoma (RCC) (Guertin and Sabatini, 2006,
2007; Hanna et al., 2008; Inoki et al., 2005). RCC comprises3%
of all adult malignancies, ranks among the top 10 cancers in theSignificance
The clinical response of RCC to mTORC1 inhibition has been m
improved by the development of mTORC1-directed mouse m
network in RCC pathogenesis. This study reports the engineer
and identification of a FoxO-Myc network as integral regulator
this circuit may provide strategies to understand the variable
motivate the development of combination treatment bymTORC
human RCC.
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conventional cancer treatments (Linehan and Zbar, 2004; Rini
et al., 2009). mTORC1 hyperactivation is observed in themajority
of human RCC samples (Pantuck et al., 2007; Robb et al., 2007)
and has emerged as a therapeutic target for RCC after several
clinical trials establishing clinical benefit of mTORC1 inhibitors
(Atkins et al., 2004; Hudes et al., 2007; Motzer et al., 2008). Given
the clinical relevance of the mTORC1 target in RCC, an under-
standing of mTORC1’s complex signaling circuitry in vivo may
inform its role in RCC pathogenesis and guide further drug devel-
opment efforts.odest. The clinical application of mTORC1 inhibitors may be
odels of RCC and by illumination of the mTORC1 activation
ing of a highly penetrant model of renal adenoma/carcinoma
s of renal tumorigenesis in mice and humans. Illumination of
clinical response to mTORC1 inhibition in RCC patients and
1 inhibitors and agents reactivating FoxO or targetingMyc in
.
Cancer Cell
FoxOs Suppress Renal TumorigenesisIncreasing knowledgeofmTORC1signaling hasdemonstrated
that mTORC1 acts both downstream and upstream of PI3K-AKT
signaling. Whereas activated PI3K-AKT signaling promotes
mTORC1 signaling through AKT-mediated phosphorylation of
both TSC2 and PRAS40, mTORC1 hyperactivation also leads
to feedback shutoff of PI3K/AKT signaling via a S6 Kinase-
dependent downregulation of upstream activators of PI3K
including the PDGF receptor and IRS-1 (Bhaskar and Hay,
2007; Guertin and Sabatini, 2007; Hay and Sonenberg, 2004;
Manning, 2004; Um et al., 2006). A major upstream regulator of
mTORC1 is the TSC1-TSC2 complex, which functions to inhibit
the mTORC1 activity via stimulation of GTP hydrolysis and inac-
tivation of small GTPase Rheb, an activator of mTORC1 (Huang
and Manning, 2008; Kwiatkowski and Manning, 2005; Li et al.,
2004). These observations hold important therapeutic implica-
tions in that, in specific genotypic contexts, mTORC1 inhibitor
treatment alone might enhance tumorigenesis in mTORC1
hyperactivation-driven tumors by stimulating PI3K-AKT-depen-
dent survival and cell cycle entry, thereby prompting calls for
combination therapeutic regimens in the clinic (Shaw and Cant-
ley, 2006). Along these lines, the rational design and effective
implementation of such combinations requires a more definitive
understanding of the key downstream effector(s) of AKT that
mediate this mTORC1-directed negative feedback circuit.
The PI3K-AKT axis is activated in virtually all human cancers
(Cully et al., 2006; Luo et al., 2003; Salmena et al., 2008; Samuels
et al., 2004). The wide range of tumorigenic phenotypes medi-
ated by PI3K-AKT signaling is consistent with the existence of
diverse downstream effectors including TSC1-TSC2 complex,
FoxOs, GSK3 and MDM2. These effectors operate in a highly
context-specific manner, i.e., effectors are coordinately or
differentially used in conferring neoplastic phenotypes in
distinct cell lineages and genotypes (Manning and Cantley,
2007). The mammalian FoxO transcription factors—FoxO1,
FoxO3, FoxO4—function in the nucleus to direct transcription
of specific gene targets governing cellular survival, proliferation,
metabolism, differentiation, and oxidative defense. Activation of
PI3K by extracellular growth factors leads to AKT-mediated
phosphorylation of FoxO1, FoxO3, and FoxO4, resulting in their
sequestration in the cytoplasm such that they are unable to regu-
late their gene targets (Accili and Arden, 2004; Greer and Brunet,
2005). The role and essentiality of the FoxOs in tumor suppres-
sion in vivo has received formal proof from murine genetic
studies wherein broad somatic deletion of all three FoxOs was
shown to engender a cancer-prone condition dominated by
hemangiomas and lymphomas (Paik et al., 2007). However, the
highly context and cell-lineage specific functions of FoxO as
revealed from this study also highlights the necessity to fully
characterize its tumor suppression function in other cell types
and tissue contexts. We studied FoxO tumor suppression func-
tion in the context of mTORC1-mediated renal tumorigenesis.
RESULTS
FoxOs Are Activated in Tsc1-Deficient Polycystic
Kidneys, but Lost in Tsc1-Deficient Renal Adenomas
and Carcinomas
To better understand the molecular and biological role of
mTORC1 hyperactivation in renal cancer development, weCanassessed the impact of homozygous deletion of Tsc1 conditional
knockout (KO) allele (Tsc1L) (Kwiatkowski et al., 2002) using
theRosa26-CreERT2 knock-in deletor allele that enables tamox-
ifen-inducible Cre-mediated excision of conditional knockout
alleles in most tissues, including kidneys (Vooijs et al., 2001).
Tamoxifen-treatment of adult Tsc1L/L, Rosa26-CreERT2 mice
resulted in efficient deletion of Tsc1 in the kidney (see Figures
S1A and S1B available online) as well as other organs (data not
shown). As recently reported (Gan et al., 2008), somatic deletion
of Tsc1 in adult mice (Tsc1L/L, Rosa26-CreERT2, hereafter
referred to as ‘‘Tsc1 KO’’) led to the development of polycystic
kidney disease (Figures 1Aa–1Ac), as well as severe hematopoi-
etic defects (data not shown) compared with littermate ‘‘Tsc1
wild-type (WT)’’ control mice (Tsc1L/L or Tsc1+/+, Rosa26-
CreERT2 mice treated with tamoxifen). All Tsc1 KO mice devel-
oped severe renal and bone marrow failure and died within
7 weeks (Gan et al., 2008). Notably, all Tsc1 KO mice developed
bilateral polycystic kidneys with >10-fold weights relative to
littermate controls (Figure 1Ac) and significantly dilated renal
tubules on histopathological analysis (Figures 1Aa and 1Ab),
which is consistent with the documented connection between
tuberous sclerosis and polycystic kidney disease (Cai and
Walker, 2006).
The Tsc1KOpolycystic kidneys exhibited increased phospho-
S6 staining compared with WT kidneys (Figure S1C), and
rapamycin treatment of Tsc1 KO mice resulted in full rescue of
the polycystic kidney defect (data not shown), strongly suggest-
ing that mTORC1 hyperactivation upon loss of Tsc1 drives the
polycystic kidney phenotype in the Tsc1 KO model. Given the
lethality of the Tsc1 KO mice, we also established a large cohort
of Tsc1L/+, Rosa26-CreERT2 mice (hereafter referred to as
‘‘Tsc1+/’’) for long-term tumor studies. Consistent with previous
reports from mice heterozygous for germ line Tsc1 null allele
(Kobayashi et al., 2001; Kwiatkowski et al., 2002), our conditional
Tsc1+/model showed renal adenomas and/or carcinomas after
long latency (>14 months) (Figures 1Ad and 2B). These renal
adenomas and carcinomas demonstrated loss of heterozygosity
(LOH) for the remaining Tsc1 allele (six of six samples examined;
data not shown) as well as increased phospho-S6 staining indic-
ative of mTORC1 hyperactivation (Figure 1C).
The long latency required for the development of Tsc1-defi-
cient renal carcinomas prompted us to consider that this model
could prove useful in the identification of physiologically relevant
checkpoint pathways activated in Tsc1 KO premalignant poly-
cystic kidneys and enable the validation of such checkpoints
through a detailed comparative analysis of activation status
of TSC-mTORC1-related signaling surrogates in Tsc1-deficient
polycystic lesions versus tumor samples. These comparative
analyses revealed strong FoxO1 and FoxO3 staining with
predominant nuclear localization (Figure 1B), a pattern consis-
tent with strong FoxO activation in Tsc1 KO polycystic kidneys
relative to WT kidney samples.
In line with these tissue findings, Tsc1 and Tsc2 KO MEFs
exhibited decreased FoxO1/3 phosphorylation compared with
WT MEFs (Figure S1D) and, accordingly, showed predominant
FoxO1/3 nuclear localization under both serum starvation and
stimulation conditions (Figure S1E). This profile corresponds
well with the anticipated constitutively high mTORC1 activity
and dramatically reduced AKT phosphorylation in Tsc-deficientcer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Inc. 473
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Figure 1. FoxOs Are Activated in Tsc1-Deficient Polycystic Kidneys, but Lost in Tsc1-Deficient Renal Adenomas and Carcinomas
(A) Gross view of Tsc1WT (left) and KO kidneys (right) at 30 days post-tamoxifen injection (DPI) at 9 weeks of age (c), hematoxylin and eosin (H&E) staining of Tsc1
WT and KO kidney sections (a and b), and Tsc1-deficient kidney tumors (d). C: carcinoma; A: adenoma; N: surrounding normal kidney cells. Scale bars, 200 mm.
(B) Immunohistochemical staining of Tsc1WT and KO kidney sections with antibodies against FoxO1 and FoxO3, showing predominant nuclear localization of
FoxO1 and FoxO3 in Tsc1 KO kidneys compared with WT kidneys. Scale bars, 20 mm.
(C) H&E and immunohistochemical staining of Tsc1 KO renal tumors with antibodies against phospho S6, FoxO1, and FoxO3, showing increased phospho S6
staining andmarked reduction or absence of FoxO1 and FoxO3 staining in Tsc1-deficient renal tumors compared with adjacent normal kidney cells. In H&E stain-
ing sections, ‘‘T’’ denotes tumor region, and ‘‘N’’ denotes adjacent normal kidney region. Scale bars, 100 mm. See also Figure S1.
Cancer Cell
FoxOs Suppress Renal TumorigenesisMEFs (Figure S1D). On this basis, we considered a model in
which the regulation of FoxO activity might play a critical effector
role in the mTORC1-AKT negative feedback circuit and that
FoxO extinction would promote tumorigenesis. In line with this
hypothesis, we observed marked reduction/loss of both FoxO1
and FoxO3 staining in all Tsc1 KO renal adenoma/carcinoma
samples examined (10 of 10 bilateral kidneys, each with multi-
ple renal adenomas/carcinomas) compared with surrounding5/10
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474 Cancer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Incnonmalignant cells (Figure 1C). Furthermore, western blotting
analysis revealed significant reduction of FoxO4 protein levels
in Tsc1-deficient renal tumors compared with adjacent normal
kidney samples (Figure S1F). Together, these data are consistent
with thepossibility that FoxOactivationparticipates in a feedback
checkpoint functioning to restrain the renal tumorigenesis initi-
ated by loss of Tsc1, and that subsequent loss of FoxO may be
required for renal cancer development in Tsc1-deficient mice.ND10/14 (72%)
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Figure 2. Dual Inactivation of FoxO and
Tsc1 Dramatically Drives Renal Tumor
Progression
(A) Kaplan-Meier overall survival analysis for mice
of indicated genotypes as a function of weeks after
tamoxifen treatment. Cohort size for each mice
colony is also indicated.
(B) Table showing the incidence of renal adenoma
and carcinoma in Tsc1+/ and Tsc1+/ FoxO/
mice at various stages. ND: not determined.
.
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FoxOs Suppress Renal TumorigenesisDual Inactivation of FoxO and Tsc1 Dramatically Drives
Renal Tumor Progression
To secure genetic evidence for the hypothetical FoxO-depen-
dent block of Tsc1 KO renal carcinoma development, we engi-
neered mice harboring conditional knockout alleles of Tsc1
and/or FoxO1/3/4, and Rosa26-CreERT2. (For simplicity, after
tamoxifen treatment to induce gene deletion, ‘‘FoxO1/3/4L/L,
Rosa26-CreERT2’’ mice will be referred to as ‘‘FoxO/’’ here-
after.) We established Tsc1+/+ FoxO+/+ (WT), Tsc1+/ FoxO/,
Tsc1+/ FoxO+/+, and Tsc1+/+ FoxO/ cohorts and monitored
survival and cancer predisposition over a period of 80 weeks.
Although there was no significant survival difference between
Tsc1+/ and WT mice, there was a marked Tsc1-dependent
reduction in lifespan of FoxO/ mice (FoxO/ mean survival
54.1 weeks versus Tsc1+/ FoxO/ mean survival 41.8 weeks,
p = 0.0002) (Figure 2A). The decrease in survival in FoxO/
mice relates to hemangiosarcomas and thymic lymphomas as
previously reported (Paik et al., 2007) and careful inspection of
the kidneys showed no evidence of renal adenoma or carcinoma
(data not shown). In contrast, Tsc1+/ FoxO/ mice showed
dramatic reduction in latency and increased penetrance of renal
adenomas and carcinomas (Figure 2B). Notably, the penetrance
and onset of FoxO/ cancer phenotypes (hemangiosarcomas
and thymic lymphomas) were not affected in Tsc1+/ FoxO/
mice. The accelerated renal tumor development in Tsc1+/
FoxO/ mice significantly contributed to the shorter life span
of Tsc1+/ FoxO/ mice compared with FoxO/ mice. These
genetic studies establish that FoxO activation is a potent block
in Tsc1 null renal tumor development in the in vivo setting.
FoxOs Are Extinguished in the Majority of Human Renal
Tumor Samples
The above data from murine model systems prompted detailed
examination of FoxO expression/activation status in human
kidney tumor samples. RCC is the most common malignancy
of the adult kidney and presents as a heterogeneous group of
tumors with distinct histological features, including clear cell,
papillary (including both type 1 and type 2), and chromophobe
RCC as well as rarer subtypes (Lopez-Beltran et al., 2006). Clear
cell RCC (ccRCC) is the predominant subtype and accounts for
up to 75%of total RCCcases (Linehan and Zbar, 2004; Rini et al.,
2009). It is generally considered that all the clear-cell tumors are
carcinomas, with greater or lesser aggressiveness, and an
adenoma state of clear cells is not accepted (Algaba, 2008).
Compared with more aggressive clear cell and papillary
subtypes, chromophobe RCCs tend to have a benign course
after surgery, provided that the tumor stage and grade are favor-
able at the time of surgery (Cohen and McGovern, 2005). Benign
epithelial neoplasms also occur in the kidney, including oncocy-
toma and metanephric adenoma, among others.
To assess FoxO expression in this spectrum of benign and
aggressive kidney tumor types, FoxO1 and FoxO3 protein abun-
dance was determined by immunohistochemistry (IHC) in
a tissue microarray (TMA) that contained 21 normal kidney
samples, 68 clear cell RCC, 10 papillary RCC, 8 chromophobe
RCC, 5 oncocytomas, as well as several rare renal tumor
subtypes. TMA-IHC analysis revealed FoxO1 and FoxO3 cyto-
plasmic and nuclear signal in both the proximal and distal tubular
epithelium in normal kidney samples (Figures 3Aa and 3Ca). InCancontrast, FoxO1 and FoxO3 signal was not detectable in the
majority of clear cell and papillary RCC samples (FoxO1: 64 of
68 clear cell and 8 of 10 papillary; FoxO3: 63 of 68 clear cell
and 7 of 10 papillary) (Figures 3A–3D). FoxO1 and FoxO3 signal
was readily detected in the tumor endothelial cells, providing
a positive internal staining control (Figure S2A; data not shown).
Notably, all of the less aggressive RCCs and benign renal tumors
retained FoxO1 and/or FoxO3 expression (Figures 3A–3D).
FoxO1 nuclear signal was especially strong in oncocytoma
samples (Figure S2B).
We also assessed phospho-S6 staining on the same TMA
sample set. This analysis revealed negative to weak phospho-
S6 staining in most normal kidney samples and moderate to
strong phospho-S6 staining in the majority of human renal clear
cell and papillary carcinomas samples (Figures 3E and 3F),
consistent with previous reports that mTORC1 hyperactivation
is observed in the majority of human RCC samples (Pantuck
et al., 2007; Robb et al., 2007). Importantly, our analysis also
showed negative to weak phospho-S6 staining in chromophobe
RCC, oncocytoma and metanephric adenoma samples (Figures
3E and 3F). The inverse staining pattern between FoxO1/3 and
phospho-S6 from different human renal tumor types provides
further support to our conclusion that FoxOs serve as a check-
point in mTORC1-activated renal tumorigenesis.
FoxO Activation Promotes Cell Cycle Arrest
and Apoptosis in Human RCC Cells
The above data prompted further examination of FoxO function
in human RCC cell lines. We first examined the expression levels
of FoxO1/3 and mTORC1 activation status in a panel of human
RCC cell lines and the immortalized WT human kidney cells
(HK2). Consistent with the data from murine renal tumors (Fig-
ure 1C), these analyses revealed that high phosphorylation levels
of S6 (surrogate of mTORC1 activation) in general correlated
with low expression levels of FoxO1 and FoxO3 in these human
RCC cell lines (Figure 4A). We then assessed the impact of FoxO
reactivation in RCC4 and UMRC2 cells that harbor low FoxO1/3
expression and high mTORC1 activation. To this end, we gener-
ated RCC4 and UMRC2 cell lines with stable expression of
FoxO1(TA)ERT2 or FoxO3(TA)ERT2 construct, which expressed
a fusion protein consisting of FoxO(TA) (containing three Ser/Thr
AKT phosphorylation sites mutated to alanine) fused to the T2-
modified estrogen receptor (ERT2) moiety (Figure S3A). We
documented that FoxO(TA)ERT2 fusion protein sequestered
FoxO(TA) in the cytoplasm and that 4OHT treatment resulted in
rapid translocation of FoxO(TA)ERT2 into nucleus (Figure S3B).
We also established stable cell lines with ERT2 expression as
control cell lines. (For simplicity, ERT2, FoxO1(TA)ERT2, and
FoxO3(TA)ERT2 cell lines will be referred to as empty vector
[EV], FoxO1, and FoxO3 thereafter). 4OHT treatment of FoxO1
or FoxO3 RCC4 cells resulted in marked cell growth suppression
compared with vehicle-treated cells or 4OHT-treated EV RCC4
cells (Figures 4B and 4C). Further analysis demonstrated that
FoxO reactivation in RCC4 cells led to potent G1/S cell cycle
arrest (Figure 4D) and enhanced apoptosis (Figure 4E). Reactiva-
tion of FoxO1/3 in UMRC2 cells resulted in similar phenotypes
(Figures S3C–S3E). Finally, in UOK101 cells that maintain
FoxO3 and FoxO1 expression, knockdown of both FoxO1 and
FoxO3 led to increased cell proliferation (Figures 4F and 4G).cer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Inc. 475
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Figure 3. FoxOs Are Extinguished in the Majority of Human Renal Tumor Samples
(A, C, and E) Representative immunohistochemical images showing FoxO1 (A), FoxO3 (C), and phospho-S6 (E) staining in normal kidney and different subtypes of
RCC samples from the TMA-IHC analysis. Scale bars, 50 mm.
(B, D, and F) Tables showing the number of tumor samples with corresponding staining scores of FoxO1 (B), FoxO3 (D), and phospho-S6 (F) in different subtypes
of RCC samples. Percentage is shown in parenthesis. , negative staining; +, low staining; ++, moderate staining; +++, strong staining. See also Figure S2.
Cancer Cell
FoxOs Suppress Renal TumorigenesisThese human RCC cell line data align with our murine data,
strongly supporting the view that FoxOs function as tumor
suppressors in the progression to human RCC.
Myc Signaling Is the Key Downstream Effector
of FoxOs in the Regulation of Renal Tumorigenesis
We next sought to determine the mechanisms by which FoxO
might govern the biology of RCC cells. To this end, we
conducted comparative transcriptome analysis of EV, FoxO1,
or FoxO3-expressing RCC4 and UMRC2 cells at 12 hr with or
without 4OHT treatment. To enrich for more proximal actions
of FoxO, we selected the 12-hr time point as time course studies
revealed dramatic transcriptional changes of known FoxO
targets (such as Cyclin D1), yet no discernible cellular pheno-
types (apoptosis and cell cycle arrest) (data not shown). We476 Cancer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Incgenerated four transcriptome data sets: FoxO1 RCC4, FoxO3
RCC4, FoxO1 UMRC2, and FoxO3 UMRC2, and normalized
these transcriptome data against 4OHT-treated EV cells that
show modest 4OHT-induced transcriptional changes (Fig-
ure 5A). As FoxO1 or FoxO3 reactivation generated comparable
phenotypes, we further intersected FoxO1 and FoxO3 transcrip-
tome data sets and focused on 503 genes exhibiting similar
changes (designated as ‘‘FoxO RCC transcriptome’’; Figure 5B;
Table S1).
Next we conducted GSEA to identify gene sets that are
enriched in FoxO RCC transcriptome. This analysis readily
identified FoxO (TTGTTT_V$FOXO4_01), hypoxia (MANALO_
HYPOXIA_DN) (Manalo et al., 2005), and E2F (V$E2F_Q6_01)
gene sets in FoxORCC transcriptome (Figure 5C; see Figure S4A
for gene set description). Most notably, the analysis revealed.
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Figure 4. FoxO Activation Promotes Cell Cycle Arrest and Apoptosis in Human RCC Cells
(A) FoxO1/3 expression and mTORC1 activation status in human RCC cells. Western blotting by various antibodies was performed on cell lysates isolated from
HK2 normal kidney cells and a panel of human RCC cell lines as indicated.
(B) Image showing the crystal violet staining of RCC4 EV, RCC4 FoxO1, RCC4 FoxO3 cells with or without 4OHT treatment for 7 days. EV, empty vector.
(C) Cell proliferation assay of RCC4 EV, RCC4 FoxO1, RCC4 FoxO3 cells with or without 4OHT treatment. *p > 0.5; **p = 6.63 105 (all refer to p values at day 7).
Data are shown as mean ± SD from at least two independent experiments with triplicates.
(D) FACS analysis showing the cell cycle profiling of RCC4 EV, RCC4 FoxO1 (F1), RCC4 FoxO3 (F3) cells with or without 4OHT treatment for 2 days.
(E) RCC4 EV, RCC4 FoxO1, RCC4 FoxO3 cells were treated with or without 4OHT for 1 or 2 days as indicated. Cell lysates were then analyzed by western blotting
with cleaved Caspase-3 and PARP as indicated.
(F) UOK101 cells were infected with ctrl (scramble) shRNA, FoxO1, and FoxO3 shRNA #1, or FoxO1 and FoxO3 shRNA #2-containing lentivirus. Cell lysates were
extracted from stable cell lines and analyzed by western blotting with FoxO1, FoxO3, and S6 as indicated.
(G) Cell proliferation assay of UOK101 ctrl shRNA cells, UOK101 FoxO1/3 shRNA #1 cells, and UOK101 FoxO1/3 shRNA #2 cells. p < 104 for comparison
between ctrl shRNA and F1/3 shRNA cells (all refer to p values at day 7). Data are shown as mean ± SD from two independent experiments with triplicates.
See also Figure S3.
Cancer Cell
FoxOs Suppress Renal Tumorigenesisa previously described Myc oncogenic signature (Bild et al.,
2006) as the most significantly enriched gene set (p = 4.51 3
1016; Figure 5C and Figure S4A). Accordingly, Myc binding
motif-containing gene set (CACGTG_V$MYC_Q2) was alsoCansignificantly enriched in FoxO RCC transcriptome (Figure 5C
and Figure S4A). The connection of FoxO to Myc signaling in
the context of RCC development is intriguing given recurrent
Myc gene amplification in human RCC (Beroukhim et al.,cer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Inc. 477
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Figure 5. Myc Signaling Is the Key Downstream Effector of FoxOs in
the Regulation of Renal Tumorigenesis
(A) Comparison of gene expression changes between RCC4 FoxO3 and
UMRC2 FoxO3, RCC4 FoxO1 and UMRC2 FoxO1 transcriptome data sets.
x and y axes show Log2 transformed fold changes in gene expression.
Genes with fold changes >1.5 or <0.67 for both x and y axes are highlighted
(with changes in the same direction in red and the opposite direction in blue,
respectively).
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478 Cancer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Inc2009), the involvement of Myc signaling in renal neoplasia as evi-
denced in genetically engineered mouse models (Schreiber-
Agus et al., 1998; Trudel et al., 1991) and human cell culture
studies (Eilers and Eisenman, 2008; Gordan et al., 2007a; Zhang
et al., 2007) (see Discussion). To understand how FoxO might
intersect with Myc signaling, we first considered a model
wherein FoxO and Myc might coregulate a common set of tran-
scription targets through cobinding on the same promoters. In
silico promoter analysis of FoxO RCC transcriptome identified
90 putative FoxO direct targets and 81 putative Myc direct
targets. However, integration of these two data sets only
revealed 12 common targets, which is statistically insignificant
(p > 0.5) (Figure S4B). Furthermore, the computational analysis
showed that the FoxO putative targets (TTGTTT_V$FOXO4_01)
are enriched in upregulated genes of the FoxO RCC transcrip-
tome, whereas Myc signature genes (MYC_ONCOGENIC_
SIGNATURE) are mostly enriched in downregulated genes of
the FoxO RCC transcriptome (Figure 5D), suggesting FoxO
might function to inhibit Myc activity and/or expression.
FoxOs Regulate Myc through Mxi-1 and mir-145
in RCC Cells
We and others previously showed that Mxi1 splicing variant
strong repressor (Mxi1-SRa), but not Mxi1 weak repressor
(Mxi1-WR), mediates antagonistic actions on Myc activity
through recruitment of Sin3A-HDAC transcriptional repressor
complex (Alland et al., 1997; Ayer et al., 1995; Heinzel et al.,
1997; Schreiber-Agus et al., 1995). Mxi1-SRa was identified to
be a FoxO direct target in other cellular contexts (Delpuech
et al., 2007). We found FoxO activation significantly upregulated
Mxi1-SRa expression while downregulating Mxi1-WR expres-
sion in both RCC4 and UMRC2 cells (Figures 6A and 6B; Figures
S5A and S5B), suggesting FoxO might inhibit Myc activity via
upregulation of Mxi1-SRa expression.
In addition, we observed FoxO reactivation resulted in signifi-
cant downregulation of Myc expression in the FoxO RCC tran-
scriptome and in confirmatory quantitative RT-PCR and western
blot analysis of RCC4 cells andUMRC2 cells (Figures 6C and 6D;
Figure S5C). The absence of FoxO binding elements in the Myc
promoter region prompted us to consider that FoxO may regu-
late microRNA(s) governing Myc expression. To test this hypoth-
esis, we examined the FoxO RCC transcriptome for enrichment
of putative targets of microRNA genes, searched the microRNA
promoter regions for putative FoxO binding elements (BEs), and
determined whether any of these microRNAs could also target
Myc via the targetScan algorithm and literature mining. This
effort identified mir-145 that is known to target Myc (Sachdeva
et al., 2009) and harbors 2 putative FoxO BEs within 2 kb(B) Venn diagram displaying common transcriptome changes of FoxO1 and
FoxO3 transcriptome data sets.
(C) The table showing the top lists of gene signatures enriched in FoxO RCC
transcriptome data set with enrichment p value indicated.
(D) The distribution of putative FoxO targets (TTGTTT_V$FOXO4_01) andMyc-
regulated genes (MYC_ONCOGENIC_SIGNATURE) in RCC4 FoxO3 transcrip-
tome data set. All genes were sorted according to expression changes in
RCC4 FoxO3 transcriptome data set (the red curve). The frequency of either
putative FoxO targets (TTGTTT_V$FOXO4_01) or Myc-regulated genes
(MYC_ONCOGENIC_SIGNATURE) in a sliding window of 1,000 sorted genes
was calculated. See also Figure S4 and Table S1.
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Figure 6. FoxOs Regulate Myc through Mxi-1 and mir-145 in RCC Cells
(A, B, C, and E) Bar graph showing the relative expression changes of Mxi1-SRa (A), Mxi1-WR (B), Myc (C), and mir-145 (E) by quantitative RT-PCR in RCC4 EV,
RCC4 FoxO1, and RCC4 FoxO3 cells with or without 4OHT treatment for 12 hr. *p > 0.1; **p = 0.04; ***p < 0.01. Data are shown as mean ± SD from two inde-
pendent experiments with triplicates.
(D) Western blotting showing endogenous Myc protein levels in RCC4 EV, RCC4 FoxO1, RCC4 FoxO3 cells at different time points after 4OHT treatment.
(F) Bar graph showing the relative expression changes of Myc, Mxi1-SRa, and mir-145 by quantitative RT-PCR in UOK101 ctrl shRNA cells, UOK101 FoxO1/3
shRNA #1 cells, and UOK101 FoxO1/3 shRNA #2 cells. p < 0.05 for comparison between ctrl shRNA and F1/3 shRNA cells in each setting. Data are shown as
mean ± SD from two independent experiments with triplicates.
(G) Endogenous FoxO1 and FoxO3 directly bind to two FoxO BEs located in mir-145 promoter region in UOK101 cells. Bar graph showing the relative enrichment
determined by quantitative RT-PCR after ChIP analysis using IgG (control), FoxO1 and FoxO3 antibodies. *p = 0.03; **p = 0.01. Data are shown asmean ± SD from
two independent experiments with triplicates.
(H) mir-145 contributes to FoxO-mediated suppression of Myc expression in RCC4 cells. Bar graph showing the relative expression levels of endogenousMyc by
quantitative RT-PCR in RCC4 EV, RCC4 FoxO1 or RCC4 FoxO3 cells with anti-mir-145 or scrambled control oligo transfection. *p > 0.5; **p < 0.01. Data are
shown as mean ± SD from two independent experiments with triplicates.
(I) Cell proliferation assay of RCC4 FoxO1 (F1) cells under different conditions as indicated. OE: overexpression; KD: knockdown. Data are shown as mean ± SD
from two independent experiments with triplicates. See also Figure S5.
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FoxOs Suppress Renal Tumorigenesisupstream ofmir-145 transcriptional start site (Figure S5D). Quan-
titative RT-PCR confirmed that FoxO3 activation can signifi-
cantly upregulate mir-145 expression in RCC4 cells (Figure 6E).
Conversely, knockdown of FoxO1 and FoxO3 in UOK101 cells
led to decrease of mir-145 and Mxi1-SRa expression, and
increase of Myc expression (Figure 6F). Furthermore, chromatin
immunoprecipitation (ChIP) analysis documented that both
ectopically expressed and endogenous FoxO1 and FoxO3 can
directly bind to both FoxO BEs in mir-145 promoter region (Fig-
ure 6G; Figure S5E). Importantly, knockdown of mir-145 by anti-
mir-145 (Figure S5F) significantly normalized Myc expression on
FoxO activation (Figure 6H), strongly suggesting that mir-145
contributes to FoxO-mediated suppression of Myc expression
in RCC cells. Consistent with recent report in other cell types
(Sachdeva et al., 2009), we found overexpression of mir-145
was sufficient to downregulate Myc expression (Figure S5G
and S5H) and inhibit cell growth in RCC4 cells (Figure S5I).
Finally, knockdown of Mxi1-SRa, knockdown of mir-145, and
overexpression of Myc, either individually or in combination,
can significantly rescue the cell growth inhibition effected by
FoxO activation in RCC4 cells (Figure 6I). Together, these data
establish that FoxO inhibits both Myc activity and expression
via transcriptional regulation of Mxi1-SRa and mir-145, and
that Myc signaling is at least one key downstream effector of
FoxO in RCC cells.
Myc/Mxi1-SRa/mir-145 Alterations in Tsc1 Renal
Cancer Mouse Models and Human RCCs
The above mechanistic studies in renal cancer cell culture
systems prompted further investigation of Myc signaling in vivo
in the context of RCC development in mice and humans. Exam-
ination of Myc/Mxi1-SRa/mir-145 status in Tsc1 mouse models
revealed that mir-145 and Mxi1-SRa expression levels were
upregulated in Tsc1KOpolycystic kidneys (with FoxO activation)
and downregulated in Tsc1 KO kidney tumors (with FoxO extinc-
tion) compared with Tsc1 WT kidneys (Figure 7A). Furthermore,
although Myc expression was downregulated in Tsc1 KO poly-
cystic kidneys comparedwith Tsc1WTkidneys (Figure 7A), there
was no obvious difference in Myc protein levels and in expres-
sion levels of Myc targets between Tsc1 KO polycystic kidneys
and Tsc1 WT kidneys (Figures 7B and 7C). Myc expression
and protein levels, andMyc target expression levels, are dramat-
ically increased in Tsc1 KO kidney tumors compared with either
Tsc1WTkidneys or Tsc1KOpolycystic kidneys (Figures 7A–7C).
Because mTORC1 hyperactivation is also known to promote
Myc translation (West et al., 1998), our data together suggest
that, in Tsc1 KO polycystic kidneys with mTORC1 hyperactiva-
tion and FoxO activation, Myc protein level is balanced by both
increased protein synthesis afforded by mTORC1 hyperactiva-
tion and decreased mRNA levels via FoxO activation. While in
Tsc1 KO kidney tumors, loss of FoxO expression leads to
increased Myc expression. This, together with increased protein
synthesis, leads to further increased Myc protein level, which
contributed to the renal tumorigenesis in Tsc1 KO mice.
Examination of Myc/Mxi1-SRa/mir-145 status in human RCCs
in published human RCC transcriptome data set (including 11
normal kidney samples and 59 ccRCC samples) (Beroukhim
et al., 2009) revealed that Myc expression was significantly upre-
gulated in ccRCCs compared with normal kidneys (Figure 7D;480 Cancer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Incp = 7.42 3 109), correlating with aforementioned data that
FoxO1/3 are extinguished in the majority of human ccRCC
samples. Further computational analyses revealed that the
mean expression levels of Myc signature genes (the same signa-
ture genes used in our FoxO RCC transcriptome analysis in Fig-
ure 5C) were significantly upregulated in ccRCCs compared with
normal kidneys (Figure S6A) (p = 4.12 3 1011) and that the
expression levels of Myc positively correlated with the mean
expression levels of Myc signature genes in ccRCC and normal
kidney samples (Figure 7E; Pearson correlation coefficient: 0.61,
p = 2.03 3 108), strongly suggesting that Myc signaling is also
upregulated in ccRCCs. We also performed RT-qPCR experi-
ments to examine the expression levels of Myc, selected Myc
targets (CCND2, GADD45A, LDHA, HK2, and ENO1), mir-145,
and Mxi1-SRa in 12 human ccRCC and matched normal kidney
samples. These experiments confirmed upregulation of Myc,
CCND2, LDHA, HK2, and ENO1, but downregulation of mir-
145, Mxi1-SRa, and GADD45A (Myc-repressed target) in ccRCC
compared with matched normal kidney samples (Figures 7F–7H;
Figures S6B–S6F). Together, our data strongly suggests that
FoxO regulation of Myc/Mxi1-SRa/mir-145 signaling network
plays a role in suppressing renal tumorigenesis in Tsc1 renal
tumor mouse model and human RCCs (Figure 7I).
DISCUSSION
The mTORC1-mediated negative feedback regulation of PI3K-
AKT (Shaw and Cantley, 2006), cancer type-specific nature of
PI3K-AKT pathway signaling in vivo, and the multiple AKT down-
stream effectors in cancer (Manning and Cantley, 2007) promp-
ted us to define mTORC1 circuitry on the genetic, genomic, and
biological levels in RCC pathogenesis. By using genetically
defined mice and human RCC cell line models, this study estab-
lishes that FoxOs play a critical role in an mTORC1-directed
negative feedback circuit in the context of renal tumorigenesis.
FoxO1 and FoxO3 are robustly activated in Tsc1-deficient
benign polycystic neoplasias as well as Tsc1 KO MEFs, and
consistently extinguished on progression to renal adenomas
and carcinomas. In addition, combined deletion of Tsc1 and
FoxO1/3/4 provoked dramatic exacerbation of the renal tumor
phenotypes, establishing activated FoxO signaling as a potent
block in Tsc1 null renal cancer development.
In elucidating the biological mechanisms by which loss of
FoxO serves to promote Tsc1 null renal cancer development,
we provide evidence that knockdown of FoxO in RCC cells leads
to increased Myc expression and enhanced cell proliferation,
supporting a model that loss of FoxO and subsequent Myc acti-
vation function to promote cell cycling at the transition from
premalignant polycystic kidney epithelial cells to adenoma in
Tsc1 mice. In addition, although FoxO is a key progression
factor, we acknowledge that loss of FoxO (and Tsc1 LOH) may
represent one of several genetic networks commandeered in
the course of kidney tumorigenesis, a view consistent with
lengthy renal tumor latency in our Tsc1+/ FoxO/ mice. Thus,
this model system may serve as a foundation for identification
of cooperative genetic events involved in renal tumorigenesis.
The FoxO family members serve as redundant tumor suppres-
sors in vivo, and FoxO1 and FoxO3 exert the major tumor
suppressor activity (Paik et al., 2007). Correspondingly, we.
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Figure 7. Myc/Mxi1-SRa/mir-145 Alterations in Tsc1 Renal Cancer Mouse Models and Human RCCs
(A) Bar graphs showing relative expression levels of Myc, Mxi1-SRa, mir-145 in Tsc1WT kidneys, Tsc1 KO polycystic kidneys, and Tsc1 KO kidney tumors. Four
samples were analyzed in each setting. p < 0.01 for comparison between Tsc1WT kidneys and Tsc1 KO polycystic kidneys (or Tsc1 KO kidney tumors) for each
gene. Data are shown as mean ± SD.
(B)Western blotting showingMyc and Vinculin protein levels in Tsc1WTkidneys, Tsc1KOpolycystic kidneys, and Tsc1KOkidney tumors. QuantifiedMyc protein
levels are also shown in the bar graph. Data are shown as mean ± SD.
(C) Bar graphs showing relative expression levels of Myc targets in Tsc1WT kidneys, Tsc1KOpolycystic kidneys, and Tsc1KOkidney tumors. Four samples were
analyzed in each setting. p > 0.05 for comparison between Tsc1WT kidneys and Tsc1 KO polycystic kidneys for each gene. p < 0.01 for comparison between
Tsc1 WT kidneys (or Tsc1 KO polycystic kidneys) and Tsc1 KO kidney tumors. Data are shown as mean ± SD.
(D) Box-plots showing Myc expression levels in ccRCC and normal kidney samples.
(E) Positive correlation between expression levels of Myc andMyc signature genes in ccRCC and normal kidney samples. x axis: expression levels of Myc; y axis:
mean expression levels of Myc signature genes; blue spots: normal kidney sample; red spots: ccRCC sample.
(F–H) The relative expression levels of Myc, Mxi1-SRa, mir-145 in 12 ccRCC samples, and matched normal kidney samples.
(I) FoxO inhibits Myc activity via transcriptional upregulation of Mxi1-SRa and downregulates Myc mRNA level via transcriptional upregulation of mir-145. Myc
signaling is the key downstream effector of FoxO to suppress renal tumorigenesis. See also Figure S6.
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FoxOs Suppress Renal Tumorigenesisobserved that FoxO1 and FoxO3 are always co-extinguished in
Tsc1-deficient mouse renal tumors and human renal tumors,
suggesting that both FoxOs need to be eliminated to bypassCanFoxO-mediated checkpoint. Furthermore, activation of FoxO1
and FoxO3 in human renal cancer cells resulted in similar cellular
phenotypes (apoptosis and cell cycle arrest) and transcriptomiccer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Inc. 481
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FoxOs Suppress Renal Tumorigenesisalterations (such as inhibition of Myc expression). Thus, we
conclude that FoxO1 and FoxO3 function as redundant tumor
suppressors in renal tumorigenesis.
In this study, we found FoxO1 and FoxO3 levels are extin-
guished in the majority of the aggressive subtypes of human
RCC, including clear cell and papillary tumors, but maintained
or robustly activated in less aggressive carcinomas (i.e., chro-
mophobe RCC) and benign tumors. The underlying mechanisms
responsible for such differential expression/activation patterns
of FoxOs in different kidney tumor types are not understood
currently. It is worth noting that recent oncogenomic analysis
identified frequent hemizygous deletions at 13q in human clear
cell RCC samples, and FoxO1was identified as a downregulated
gene in the minimal common region of the 13q deletion (Kojima
et al., 2010), suggesting that genomic alteration might be at
least a contributing mechanism for the loss of FoxO1 staining
in our analysis. We speculate that other mechanisms operating
on the epigenetic and posttranslational levels might be also
involved in effecting extinction of FoxO expression/activity in
these RCC samples.
Our integrated transcriptomic, computational, and functional
studies identified Myc-Mxi1 signaling as the key downstream
effector of FoxOs in the regulation of renal cancer cell prolifera-
tion. This finding is particularly intriguing in light of our previous
work showing that deletion of Mxi1 in mice led to the develop-
ment of polycystic kidney disease (PKD) similar to the PKD
observed in Tsc1-deficient mice (Schreiber-Agus et al., 1998).
Notably, Myc transgenic mice also developed PKD (Trudel
et al., 1991). These mouse genetic studies thus provide impor-
tant complementary evidence to our computational and func-
tional analyses in support of the critical function of Myc-Mxi1
signaling in mTORC1-FoxO-directed renal tumorigenesis.
Myc and Mxi1 are also highly relevant to human RCC. Recent
oncogenomic profiles show that Myc is amplified in about 12%
clear cell RCC samples and is the only gene in the 8q amplifica-
tion peak region, confirming Myc as an oncogene in human
kidney cancer (Beroukhim et al., 2009). Furthermore,Mxi1 locus
is subjected to homozygous and hemizygous deletion in a subset
of clear cell RCC samples (Beroukhim et al., 2009), suggesting
that Mxi1 functions as a tumor suppressor in human kidney
cancer. Mechanistically, it has been shown that Myc can cross-
talk with HIF signaling to regulate cell cycle entry, metabolism,
and mitochondrial biogenesis in RCC cells (Dang et al., 2008;
Gordan et al., 2007a, 2007b; Zhang et al., 2007). Further study
will be necessary to investigate whether FoxO can regulate
cancer cell metabolism and mitochondrial biogenesis in the
context of renal tumorigenesis via Myc signaling.
Finally, our data also point to combination therapeutic regi-
mens for improved treatment of renal cancer. Specifically,
because our study demonstrated that FoxOs are extinguished
in the majority of human RCC samples and serve as an critical
tumor suppressor axis in renal cancer, it predicts that mTORC1
inhibition (or mTORC1/PI3K inhibition) would not affect the
downstream oncogenic effect afforded by loss of FoxO, which
explains, at least in part, why mTORC1 inhibition has relatively
limited impact on kidney cancer patients. Our study further sug-
gests combination therapy by mTORC1 inhibition and a FoxO
restabilization/activation and/or Myc destabilization strategy
might provide improved treatment in kidney cancer. As dis-482 Cancer Cell 18, 472–484, November 16, 2010 ª2010 Elsevier Inccussed above, currently we favor a model that FoxO extinc-
tion in human RCC might result from posttranslational mecha-
nism (such as phosphorylation-mediated protein degradation).
Further understanding of how FoxOs are extinguished in human
RCC might therefore provide treatment strategies in RCC,
including such strategies as blocking Crm1-mediated nuclear
export. Alternatively, our study suggests that combined inhibi-
tion of mTORC1 and Myc signaling might further improve
the treatment of kidney cancer. Interference of Myc signaling
may be provided by current efforts to target Myc heterodimeriza-
tion with Max or by targeting factors regulating Myc protein
degradation.
In summary, this integrated genetic, transcriptomic, computa-
tional, and cell biological study has provided additional insights
into the molecular basis of mTORC1-mediated negative feed-
back in the context of renal tumorigenesis. Our study identifies
FoxO transcription factors as a critical checkpoint that functions
to constrain mTORC1-mediated renal tumorigenesis and serves
as a tumor suppressor axis in renal cancer. Further study of the
FoxO network may illuminate additional points of therapeutic
intervention and provide pharmacodynamic markers for guiding
the development of agents targeting components of the PI3K
pathway in RCC patients.
EXPERIMENTAL PROCEDURES
Generation and Analysis of Mice
The Rosa26-CreERT2mice (Vooijs et al., 2001) were mated with FoxO1/3/4L/L
mice (Paik et al., 2007) to generate FoxO1/3/4L/L, Rosa26-CreERT2 mice,
which were then crossed with Tsc1L/L mice (Kwiatkowski et al., 2002) to
generate various mice lines with desired genotypes. All cohorts were in
a FVB/n, C57Bl/6, and 129/Sv mixed genetic background. Littermates at
4–5 weeks of age were treated daily by intraperitoneal injection of tamoxifen
in corn oil (0.13 mg/g body weight) for 5 consecutive days (Gan et al., 2008).
The tamoxifen was intended to induce CreERT2 translocation into the nucleus,
thereby leading to transient Cre-mediated recombination. Overall survival, as
well as spontaneous formation of tumors, was monitored in various cohorts.
Animals were autopsied and all tissues were examined regardless of their
pathological status. All animal manipulations were performed with Harvard’s
and Dana-Farber Cancer Institute’s Institutional Animal Care and Use
Committee (IACUC) approval.
Human Samples
Human RCC TMA and RNA samples were obtained from Renal Cancer Tissue
Acquisition, Pathology, and Clinical Data Core (TAPCD) at Dana-Farber/
Harvard Cancer Center (DF/HCC) Kidney Cancer SPORE directed by S.S.
All patients provided informed consent and the study was approved by the
Institutional Review Boards of Dana-Farber Cancer Institute and DF/HCC
Renal Cancer TAPCD Core Utilization Committee (RCTUC).
Antibodies for Immunohistochemistry and Western Blot Analysis
The following antibodies were used: Vinculin (Sigma), Myc (sc-42, Santa Cruz,
to detect endogenous Myc), Myc (9E10, Santa Cruz, to detect Myc tag), S6K
(Santa Cruz), TSC1, FoxO1 (C29H4), FoxO3 (75D8), FoxO4, Thr24 phospho-
FoxO1/Thr32 FoxO3, AKT, Ser473 phospho AKT, S6, Ser240/244 phospho-
S6, Thr389 phospho-S6K, PARP, and cleaved-Caspase 3 (all from Cell
Signaling Technology).
Constructs and Reagents
FoxO1(TA) and FoxO3(TA) cDNAs were obtained from addgene, and then
were fusedwithMyc-tagged ERT2 at C terminus and cloned in retroviral vector
pBabe. Myc expression construct is described in our recent publication
(Zheng et al., 2008). Lentiviral shRNA vectors targeting human Mxi1 and non-
targeting control construct shGFPwere obtained from the RNAi Consortium at.
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FoxOs Suppress Renal Tumorigenesisthe Dana-Farber/Broad Institute. Lentiviral mir-145 expression vector was
purchased from System Biosciences. Anti-mir-145 and scrambled oligos
were ordered from Exiqon.
Cell Culture Studies
Immortalized human kidney cells (HK2), human kidney cancer cell lines used in
this study, and human embryonic kidney cell line HEK293T were purchased
from American Type Culture Collection (ATCC). Lentiviruses or retroviruses
were produced in HEK293T cells with packing mix (ViraPower Lentiviral
Expression System, Invitrogen) and used to infect target cells as per manufac-
turer’s instruction. To reactivate FoxO, FoxO1(TA)ERT2 or FoxO3(TA)ERT2
cells were treated with 100 nM 4OHT or vehicle for different periods of time
as indicated and subjected to various analyses. Cell proliferation assays
were performed in 12-well plates in triplicate with 10,000 cells per well. Cells
were fixed in 10% formalin in PBS, and stained with crystal violet at different
days as indicated. At the conclusion of the assay, crystal violet was extracted
with 10% acetic acid and absorbance at 595 nm was measured with 96-well
plate reader.
ChIP Analysis
Chip experiment was performed using EZ-Chip Kit (Chemicon) as per manu-
facturer’s instruction.
Expression Profiling and Quantitative Real-Time PCR Analysis
Details of expression profiling and quantitative real-time PCR analysis are
provided in Supplemental Experimental Procedures.
Statistical Analysis
Tumor-free survivals were analyzed using GraphPad Prism4. Statistical anal-
yses were performed using nonparametric Mann-Whitney test. Comparisons
of cell growth and gene expression were performed using the unpaired
Student’s t test. For all experiments with error bars, standard deviation was
calculated to indicate the variation within each experiment and data, and
values represent mean ± standard error of mean.ACCESSION NUMBERS
Completed microarray data have been deposited in the Gene Expression
Omnibus website with accession code GSE23926.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, six figures, and one table and can be found with
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